Effect of intravenous ondansetron on sensory and motor block after spinal anaesthesia with hyperbaric bupivacaine

Anaesthesia and Intensive Care

Volumn 39, Issue 1, 2011, Pages 65-68

  Samra, T ^a   Bala, I ^a   Chopra, K ^a   Podder, S ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Bupivacaine; Duration; Ondansetron; Spinal anaesthesia

Indexed keywords

BUPIVACAINE; ONDANSETRON; PLACEBO;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BLADDER TUMOR; DERMATOME; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; HEMODYNAMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; OPERATION DURATION; RANDOMIZED CONTROLLED TRIAL; SHIVERING; SPINAL ANESTHESIA; TRANSURETHRAL RESECTION;

EID: 79551569599     PISSN: 0310057X     EISSN: 14480271     Source Type: Journal    
DOI: 10.1177/0310057x1103900110     Document Type: Article

References (16)

1. Milne RJ, Heel RC. Ondansetron: therapeutic use as an antiemetic. Drugs 1991; 41:574-595.
2. Alhaider AA, Lei SZ, Wilcox GL. Spinal 5-HT3 mediates antinociception: possible release of GABA. J Neurosci 1991; 11:1881-1888.
3. Besson JM, Chaouch A. Peripheral and spinal mechanisms of nociception. Physiol Rev 1987; 67:67-186.
4. Fassoulaki A, Sarontopoulos C, Melemeni A, Zotou M. Systemic ondansetron antagonizes the sensory block produced by intrathecal lidocaine. Anesth Analg 2005; 100:1817-1821. (Pubitemid 40712746)
5. Mowafi HA, Arab SA, Ismail SA, Al-Ghamdi A. The effects of intravenous granisetron on the sensory and motor blockade produced by intrathecal bupivacaine. Anesth Analg 2008; 106:1322-1325.
6. Paraskeva A, Chatziara V, Siafaka I, Zotou M, Fassoulaki A. Ropivacaine spinal anesthesia is not antagonized by ondansetron pretreatment. Anesth Analg 2009; 109:1684-1687.
7. Tramier MR, Moore RA, Reynolds DJM, McQuay HJ. Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials. Anesthesiology 1997; 87:1277-1289.
8. Liu SS, Pollock JE, Mulroy MF, Allen HW, Neal JM, Carpenter RL. Comparison of 5% with dextrose, 1.5% with dextrose, and 1.5% dextrose free lidocaine for solutions for spinal anesthesia in human volunteers. Anesth Analg 1995; 81:697-702.
9. McDonald SB, Liu SS, Kopacz DJ, Stephenson CA. Hyperbaric spinal ropivacaine. Anesthesiology 1999; 90:971-977.
10. Zaric D, Christiansen C, Pace NL, Punjasawadwong Y. Transient neurologic symptoms after spinal anesthesia with lidocaine versus other local anesthetics: a systematic review of randomized, controlled trials. Anesth Analg 2005; 100:1811-1816.
11. Blower PR. Granisetron: relating pharmacology to clinical efficacy. Support Care Cancer 2003; 11:93-100.
12. Bloomer JC, Baldwin SJ, Smith GJ, Aryton AD, Clarke SE, Chenery RJ. Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br J Clin Pharmacol 1994; 38:557-566.
13. Dixon CM, Colthup PV, Serabjit-Singh CJ, Kerr BM, Boehlert CC, Park GR et al. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 1995; 23:1225-1230.
14. Murphy RM, Zemlan FP. Selective serotonin 1A/1B agonists differentially affect spinal nociceptive reflexes. Neuropharmacology 1990; 29:463-468.
15. Ali Z, Wu G, Kozlov A, Barasi S. The role of 5HT3 in nociceptive processing in the rat spinal cord: results from behavioural and electrophysiological studies. Neurosci Lett 1996; 208:203-207.
16. Morales M, De Wang S. Differential composition of 5-hydroxytryptamine3 receptors synthesized in the rat CNS and peripheral nervous system. J Neurosci 2002; 22:6732-6741. (Pubitemid 35386429)